(Reuters) – U.S. The government has set up AstraZeneca PLC. Has been awarded million 1 million million to develop and protect up to 100,000 doses of COVID-1 anti-antibody treatment, the same class of drug used in President Donald Trump’s treatment. Was coming.
The U.S. Department of Health and Human Services said the agreement is aimed at developing a single-antibody cocktail under the Trump administration’s operational pace, which could prevent COVID-19, especially those over the age of 80 at high risk. In the population.
The treatment came under discussion last week after Trump was treated with the antibody drug Regeneron Pharmaceuticals. The president has also released a video on Twitter highlighting its benefits.
In a call early Friday, a senior U.S. health official said the government expects Trump to provide more than 1 million free doses of antibody treatment for Covid-19 patients being administered.
Regeneron and Ally Lilly are both U.S. Have applied to the Food and Drug Administration for approval of the emergency use of their antibody therapy.
AstraZeneca said it plans to supply up to 100,000 doses starting by the end of 2020 and that the US government could receive an additional 10 million doses in 2021 under a separate agreement.
Regenerators signed a 4 50,450 million deal in July to sell a sufficient amount of its antibody treatment, REGN-COV2, to treat an estimated 300,000 people.
Eli Lilly said Friday that he has not signed an agreement with Operation Spearm Speed.
AstraZeneca plans to evaluate the treatment, AZD42, 42૨, which is a cocktail of two monoclonal antibodies in two studies.
One trial will evaluate the safety and effectiveness of experimental treatment to prevent infection in about 1,000 participants for 12 months, while another will evaluate approximately 1,100 participants in post-exposure preventive and pre-free treatment.
Report by Ankur Banerjee in Bengaluru; Edited by Anil de Silva
.
